Insmed reported $-127697000 in Operating Profit for its third fiscal quarter of 2022.


Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
width
height
Operating Profit Change
DBV Technologies DBVT:US USD -18020000 5.8M
Acelrx Pharmaceuticals ACRX:US USD -6632000 6.94M
Alimera Sciences ALIM:US USD -3411000 1.44M
Biomarin Pharmaceutical BMRN:US USD -2417000 41.57M
Cytokinetics CYTK:US USD -130687000 119.81M
Dynavax Technologies DVAX:US USD 61.4M 66.83M
Gilead Sciences GILD:US USD 2.84B 808M
Heron Therapeutics HRTX:US USD -41882000 7.62M
Insmed INSM:US USD -127697000 39.38M
Mirati Therapeutics MRTX:US USD -186443000 9.24M
Novartis NVS:US USD 2.17B 60M
Regeneron Pharmaceuticals REGN:US USD 1.22B 113.8M
Sarepta Therapeutics SRPT:US USD -256796000 45.66M
Seattle Genetics SGEN:US USD -192805000 59.69M
Ultragenyx Pharmaceutical RARE:US USD -225066000 83.47M
Vertex Pharmaceuticals VRTX:US USD 1.13B 20.4M